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Purpose: This study attempted to estimate the utility weights for hypothetical chronic obstructive pulmonary
disease (COPD) health states, including the effect of exacerbation, and based on utilities elicited from a
representative sample using the time trade-off (TTO).
Methods: A total of 200 study subjects were recruited using a quota sampling method in Seoul, Korea. Ten COPD
health profiles were described reflecting the severity of COPD and the extent of exacerbation. Respondents
evaluated each health state using a visual analogue scale and TTO during a personal interview. TTO values were
estimated using a linear mixed model, and the model performance was evaluated in terms of its predictive ability
and goodness of fit.
Results: The estimated TTO values were 0.824 in moderate, 0.646 in severe, and 0.305 in very severe COPD health
states. The estimated utility decrements in TTO varied from 0.082 for a non-serious exacerbation to 0.228 for one
non-serious plus one serious exacerbation per year. The mean absolute error of the TTO model was 0.008, and the
generalized R2 was 0.86.
Conclusion: The social preference of various COPD health states and the utility decrement due to exacerbation can
be useful for the economic evaluation of COPD intervention in Korea.
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Chronic obstructive pulmonary disease (COPD) is char-
acterized by persistent airflow limitation which is usually
progressive and associated with an enhanced chronic in-
flammatory response in the airway and lung to noxious
particles or gases. COPD is a leading cause of morbidity
and mortality worldwide, and its prevalence and mortal-
ity rates are currently rising [1]. As a result, the increas-
ing economic and social burden of COPD is substantial
[2]. COPD patients have a low health-related quality of
life (HRQOL), especially in terms of physical, emotional,
and mental health [3].
HRQOL refers to the physical, psychological, and so-
cial domains of health which are seen as distinct areas* Correspondence: mdjominwoo@gmail.com
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unless otherwise stated.that are influenced by a person’s experiences, beliefs, ex-
pectations, and perceptions [4]. Utility is a preference
that individuals or societies may have for any particular
set of health outcomes and which is useful in measuring
HRQOL adjustment to a given set of treatment out-
comes [5]. This utility is used for economic evaluation
such as cost-utility analysis (CUA), medical decision
making in a clinical setting, and evaluation and monitor-
ing of population health [6]. Utilities are obtained either
via direct valuation techniques, such as standard gamble,
time trade-off (TTO), and the use of a rating scale, or
indirectly via generic preference-based life instruments
such as EQ-5D.
COPD is characterized by fluctuations in symptoms
and quality of life, although the disease generally pro-
gresses slowly over a period of many years [7]. The goal
of COPD management includes symptom relief and risk,
i.e. disease progression, exacerbation, and mortality,is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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according to the disease severity and exacerbation, are re-
quired in order to conduct economic evaluation regarding
COPD intervention. In previous studies, utilities in differ-
ent COPD states and the impact of disease exacerbation
varied substantially [8-10]. Evidence suggests that the
EQ-5D for COPD and its exacerbations has limited
discriminatory ability, particularly between moderate and
severe COPD, and that the responsiveness to clinically
relevant changes in stable COPD over time, due to treat-
ment, also appears limited [11-13]. This utility may also
differ according to the perspective or type of interviewee,
such as patients, physicians or the general population [14].
The purposes of this study are to elicit a social value
for COPD health states that describe the commonly oc-
curring combination of COPD severity and exacerbation
patterns through TTO and the visual analogue scale
(VAS) and to develop a prediction model to estimate the
utility weights of COPD states in the Korean population.
We also attempted to compare the utility weights be-
tween the general population and health professionals.
Methods
Study population
This study was approved by the Institutional Review
Board of Asan Medical Center (approval number: 2011–
0119). The target general population consisted of adults
aged 19 years or older living in Seoul, Korea. Quota
sampling was used and proportionally represented the
2010 national census in terms of age and sex. All partici-
pants provided written informed consent. Each respond-
ent was asked to complete the questionnaire during a
face-to-face interview. The survey was performed from
13 April 2012 to 11 May 2012 by 10 interviewers trained
in evaluating methods. Health professionals involved in
the care of COPD patients were also interviewed regard-
ing the same evaluation task.
Questionnaire and health profiles
The questionnaire consisted of questions regarding demo-
graphic factors, i.e. sex, age, and level of education, and
the self-perceived health status using EQ-5D, followed
by evaluation of 10, COPD health profiles using both
the VAS and TTO methods. The 10, COPD health pro-
files were developed based on the study by Rutten-van
Mölkenet al. [7] and were modified after consultation with
a respiratory specialist. Each health profile included one of
the three levels of severity of COPD, i.e. mild, moderate or
severe COPD approximately corresponding to a grade of
II, III or IV, respectively, based on the Global Initiative for
Chronic Obstructive Lung Disease [GOLD] grades [15] as
well as information regarding the frequency and severity
of symptom exacerbation. The COPD severity was de-
scribed in terms of six dimensions: (i) extent of dyspnea;(ii) impact on non-strenuous activities; (iii) impact on
strenuous activities; (iv) ability to work; (v) anxiety and de-
pression; and (vi) energy and tiredness. Each dimension
consisted of three levels (Additional file 1: Appendix 1).
The exacerbation extent was categorized as non-serious
and serious exacerbation. Exacerbation was operation-
ally described in terms of three aspects: (i) symptoms in
both the respiratory and non-respiratory system and im-
pact on daily activities; (ii) required treatment; and (iii)
symptom duration (Additional file 1: Appendix 2).
In this study, each COPD health status was expressed
as a three-digit number, with the first digit indicating
whether the patient suffered from moderate (1), severe
(2) or very severe (3) COPD. The second digit indicates
the number of non-serious exacerbations (0 or 1), and
the third digit indicates the number of serious exacerba-
tions (0 or 1). For example, the profile 211 refers to
moderate COPD with one non-serious and one serious
exacerbation once a year for 10 years. The 10 possible
health states were 100, 110, 200, 210, 201, 211, 300, 310,
301, and 311. The profiles 101 and 111 were not evalu-
ated in this study, because we assumed that serious ex-
acerbation is rare in the moderate COPD according to
the results of consultation with COPD specialists. An
operational definition of non-serious exacerbation and
serious exacerbation was described on the questionnaire.
Interviews
First of all, respondents evaluated 10 COPD health states
on a 20-cm vertical VAS in which the endpoints were la-
beled ‘100 = Best imaginable health state’ and ‘0 =Worst
imaginable health state’. Death was finally evaluated after
evaluation of 10 hypothetical health states. Next, they
evaluated 10 COPD health states using the TTO method
after dividing those states into “better than death” states
and “worse than death” states. For “better than death”
states, the interviewers attempted to determine a re-
spondent’s point of indifference between the length of
time (t) in the best imaginable health state and 10 years
in the target health state. “Worse than death” states were
not evaluated to reduce the cognitive burden of respon-
dents in the TTO method. In both valuation methods,
the respondents were asked to imagine living in each tar-
get health state for 10 years. The smallest tradable unit in
the TTO method was one year and a ping-pong approach
was applied [16]. Furthermore, we used the duration in
full health for the response scale and visual aids were
not used.
Analysis
Calculation of utility weights
Utility weights on VAS for the health states were given by
the formula (x-d)/(100-d), where x was the scale place-
ment of the health state and d was the scale placement of
Table 1 Demographic characteristics of the survey
participants and national data
Characteristics All study respondents KNHANES IIIa
N (%) %
Sex
Female 102 (51.0) 50.7
Age
20–29 46 (23.0) 23.4
30–39 48 (24.0) 24.2
40–49 44 (22.0) 23.4
50–59 39 (19.5) 17.9
60 and older 23 (11.5) 11.0
Level of education (years)
9 and below 13 (6.5) 20.9
10 to 12 95 (47.5) 41.4
13 and more 92 (46.0) 37.8
Reported problem in the EQ-5D dimension
Mobility 3 (1.5) 8.4
Self-care 1 (0.5) 1.6
Usual activities 4 (2.0) 5.2
Pain/discomfort 28 (14.0) 21.9
Anxiety/depression 22 (11.0) 12.6
EQ-5D index, mean (SD) 0.978 (0.05) 0.943
EQ-VAS, mean (SD) 82.7 (11.8) 73.9
aKorean National Health and Nutrition Examination Survey III (2007 ~ 2009) data.
The frequencies and means are weighted based on the population distribution.
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states ‘better than death’ were calculated using the formula
t/10, where t represented the number of years spent in the
best imaginable health. Utility weights for states ‘worse
than death’ were given a zero. Possible TTO utility weights
ranged from 0 to 0.992. Logical consistency was applied
for each given pair of health states, i.e. if one state of a
pair is clearly better than the other state, after which
the evaluation for the former state must be at least as
good as the valuation for the later state [18]. For ex-
ample, a health state of ‘200’must be at least as good
as a health state of ‘301’.
Statistical analysis
To assess the comparability of the two measurement
techniques at the aggregate level, we assessed the mean
difference in score between the two techniques [19]. The
Wilcoxon rank sum test was also used to evaluate the
null hypothesis of an average mean difference of zero,
and the Spearman correlation coefficient was used to
evaluate the relationship between the differences in the
utility scores and the mean utility scores. Because the data
were a sample of the population, linear mixed models at
the individual level were used to estimate the VAS and
TTO utility weights in order to predict values for other
members of that population. The dependent variable was
the VAS or TTO utility weight. The basic explanatory
variables were the severity of the COPD health state and
the occurrence of non-serious exacerbation or serious
exacerbation, both of which were treated as dummy
variables. We also explored models with interaction
effects between the COPD severity and the occurrence
of exacerbation and/or variables such as patient age,
sex, education, and self-perceived health status. The
predictive ability of the model was assessed using the
mean absolute error (MAE which is the average of the
absolute differences between the observed and predicted
values and is considered to be an important model selec-
tion indicator. A smaller MAE indicates a better model.
Generalized R2 was also determined in order to assess
goodness of fit in the prediction models. Statistical ana-
lyses were conducted using the SAS software (ver.9.1,
Cary, NC), and P < 0.05 was considered to be statistically
significant.
Results
Among the 323 study subjects contacted for interviews,
200 interviews (61.9%) were successfully conducted. The
demographic characteristics and self-perceived health state
for survey respondents and the Korean National Health
and Nutritional Examination Survey III (KNHANES III)
[20] are presented in Table 1. The mean age of study par-
ticipants was 41.3 years (SD ± 11.3), and 51% were women.
The mean EQ-5D index of the study subjects was 0.978(SD ± 0.05). Problems reporting the rate in each dimension
were less than in those from the KNHANES III. A total of
22 physicians (mean age, 41.2 [SD ± 4.8], 27% women] par-
ticipated in the interviews.
All data fulfilled logical consistency requirements and
were therefore included in the analysis. There were no
statistically significant demographic factors and self-
perceived health status variables seen as explanatory var-
iables in the model. Therefore, the model using basic ex-
planatory variables in both the VAS and TTO methods
was selected as the preferred model. Parameter estimates
for models with VAS and TTO values in the general
population and for health professionals are presented in
Table 2. In the general population, the VAS values ranged
from 0.750 in 100 (moderate COPD without exacerba-
tion) to 0.046 in 311 (very severe COPD having one,
non-serious exacerbation and one, serious exacerba-
tion per year). The TTO values ranged from 0.824 in
100 to 0.077 in 311. In the TTO model, the decreases
in utility were estimated to be 0.082 for a non-serious
exacerbation and 0.228 for both a non-serious and
serious exacerbation. The MAE was 0.008 (SD, 0.006)
in the VAS model and 0.008 (SD, 0.007) in the TTO
Table 2 Parameter estimates for the VAS and TTO models using a linear mixed model in the general population and in
health professionals
Parameter Visual analogue scale Time trade-off
Coefficient (SE) p-value Coefficient (SE) p-value
General population
Intercept = moderate COPD 0.750 0.009 <0.0001 0.824 0.011 <0.0001
Severe COPD −0.179 0.005 <0.0001 −0.178 0.006 <0.0001
Very severe COPD −0.482 0.005 <0.0001 −0.519 0.006 <0.0001
One non-serious exacerbation −0.078 0.004 <0.0001 −0.082 0.005 <0.0001
One serious exacerbation −0.155 0.005 <0.0001 −0.164 0.006 <0.0001
One non-serious and one serious exacerbation −0.217 0.005 <0.0001 −0.228 0.006 <0.0001
Generalized R2 0.83 0.86
MAE, mean (SD) 0.008 (0.006) 0.008 (0.007)
Health professionals
Intercept = moderate COPD 0.759 0.027 <0.0001 0.883 0.025 <0.0001
Severe COPD −0.226 0.014 <0.0001 −0.234 0.016 <0.0001
Very Severe COPD −0.496 0.014 <0.0001 −0.590 0.016 <0.0001
One non-serious exacerbation −0.072 0.012 <0.0001 −0.070 0.014 <0.0001
One serious exacerbation −0.147 0.014 <0.0001 −0.148 0.017 <0.0001
One non-serious and one serious exacerbation −0.196 0.014 <0.0001 −0.207 0.017 <0.0001
Generalized R2 0.93 0.88
MAE, mean (SD) 0.004 (0.003) 0.011 (0.008)
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in the VAS and TTO models, respectively. Among
factors, the severity of ‘severe’ had the largest impact
in all models. In health professionals, the regression
coefficients in the VAS and TTO models were similar
to those of the general population.
The observed and estimated utility weights for the 10
COPD health states are shown in Table 3. In this study,
the COPD state of 111 and 211 showed the largest ab-
solute difference between the observed weights andTable 3 Observed and predicted mean values of 10 COPD hea
COPD health states Visual anal
Observed
Moderate state without exacerbation 0.753
Moderate state with 1 non-serious exacerbation 0.670
Severe state without exacerbation 0.583
Severe state with 1 non-serious exacerbation 0.502
Severe state with 1 serious exacerbation 0.413
Severe state with 1 non-serious +1 serious exacerbation 0.339
Very severe state without exacerbation 0.254
Very severe state with 1 non-serious exacerbation 0.186
Very severe state with 1 serious exacerbation 0.116
Very severe state with 1 non-serious +1 serious exacerbation 0.067estimated weights at 0.016 in the VAS and 0.019 in
the TTO model. The average difference between the ob-
served mean TTO and the VAS values was 0.054, and
which was statistically significant in the general population
(p = 0.005) in which the VAS and TTO means were the
proportionate differences between the TTO and VAS
means (Spearman correlation ρ = 0.84, p = 0.002). The
TTO values were higher than the VAS values for all health
states in both the general population and in health profes-
sionals (Figure 1).lth states in the general population
ogue scale Time trade-off
Predicted Difference Observed Predicted Difference
0.750 0.003 0.820 0.824 −0.004
0.673 −0.003 0.746 0.743 0.004
0.572 0.011 0.658 0.646 0.012
0.494 0.007 0.572 0.565 0.007
0.416 −0.003 0.482 0.482 0.000
0.355 −0.016 0.400 0.419 −0.019
0.268 −0.014 0.297 0.305 −0.008
0.191 −0.004 0.212 0.224 −0.011
0.113 0.003 0.141 0.141 0.000
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Figure 1 Observed visual analogue scale (VAS) and time trade-off (TTO) values for COPD health states according to the type of respondent.
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In this study, the TTO and VAS values for the COPD
health states were elicited from 200 respondents of the
general population in South Korea using random effects
regression. The value differences between the valuation
techniques in the respondent groups were also investi-
gated. A model using the VAS scores as dependent vari-
ables showed a good predictive ability and goodness of
fit comparable to those of the TTO model. However,
substantial differences were noted between the TTO
values and the VAS scores. Furthermore, VAS scores are
prone to bias and do not use an interval scale of prefer-
ence [21,22]. For these reasons, a model using TTO
values was recommended to calculate the utility weights.
In the TTO model, all regression coefficients were sta-
tistically significant and showed logically consistent pre-
dictions, i.e. TTO values decreased with increasing
severity of the COPD health state and the extent of ex-
acerbation. Very severe COPD showed the largest influ-
ence on utility estimates. The difference in the utility
estimates between severe and very severe COPD was ap-
proximately three times larger than the difference be-
tween moderate and severe COPD. Our study showed
lower utilities in moderate (0.824), severe (0.646), and very
severe COPD (0.305) compared to the values (0.929,
0.717, and 0.522, respectively) previously reported in a
study by Rutten-van Mölken et al. and which was based
on a profile approach [7].
Health professionals also deemed the extent of the
utility decrease with the increasing severity of COPD
profiles and frequency and the severity of exacerbation
to be larger than did the general population. However,
the difference was not statistically significant. The util-
ities elicited from health professionals were used toassess the preference of doctors for recommending cer-
tain therapeutic options to patients. We hypothesized
that because health professionals personally witness the
patient’s course of COPD, they gave poorer scores than
did the general population group which simply imagined
hypothetical disease scenarios. Similarly, Owens et al. re-
ported that in the case of HIV, physicians gave lower
quality of life scores for severe conditions than did pa-
tients [23], as reported in a study by Tsevat et al. [24].
In this study we compared COPD utilities according
to the GOLD stage which was measured by EQ-5D ap-
plying a UK-based algorithm. Rutten-van Mölken et al.
[25] and Stahl et al. [26] reported mean utility scores of
0.787, 0.750, and 0.647 and 0.73, 0.74, and 0.52, respect-
ively, for moderate, severe, and very severe COPD. A
systematic review reported pooled mean utility scores
according to the GOLD stage of 0.74 (range, 0.66–0.83)
in moderate, 0.69 (0.60–0.78) in severe, and 0.61 (0.44–
0.77) in very severe COPD [27]. The value for moderate
COPD in both studies was lower than that of our present
study, while the value for severe and very severe COPD in
both studies was higher than that of our present study. A
possible reason for these discrepancies is that the classi-
fication of the GOLD stage was based on the pulmonary
function test in previous studies, while our current classifi-
cation was based on various dimensions, including breath-
lessness and the impact of daily activities. In addition, a
previous study reported only a weak correlation between
the forced expiratory volume per second and the patient’s
HRQOL [28].
Exacerbation contributes considerably to the total costs
of COPD [29,30], and utility weights at exacerbation are
critical to the CUA analysis of COPD. However, reported
utility weights at exacerbation have been highly variable in
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model, Borg et al. applied utility decrements of 5% to 70%
(0.045 to 0.384) of the original QALY (quality-adjusted
life year) weights depending on the severity of exacerba-
tion based on an expert opinion [31]. Oostenbrink et al.
applied a utility value decrease of 15% in non-severe ex-
acerbation and 50% in severe exacerbation (0.113 to
0.274) [8]. Sin et al. assumed the reduction to be 0.32
QALYs for each exacerbation episode regardless of the
severity of the exacerbation [9]. In a study by Rutten-van
Mölken et al. using a profile-based approach, the esti-
mated annual utility decrements were 0.010 and 0.042
for one non-serious and one serious exacerbation per
year, respectively, while it was 0.088 for having both one
serious and one non-serious exacerbation per year [7].
The utility decrements of exacerbation in our study ap-
pear to be much larger, ranging from 0.082 for one non-
serious exacerbation to 0.228 for having both one ser-
ious and one non-serious exacerbation per year. The
reason for these differences in utility weights is unclear
and may be partly attributed to cultural divergence and
differences in the survey methodology, i.e. questionnaire
format and application method. In our study, there was
no interaction between the severity of COPD and the
extent of exacerbation, such that utility decreases due
to exacerbation were similar regardless of the COPD
severity. This finding has been observed in previous
studies [7,32].
The age and gender of the respondents in this study
were similar to those of the Korean general population,
while the educational level in study respondents was in-
clined to be higher than those of the general population.
The effects of the educational level on evaluation tasks
remain unknown. Dolan et al. reported that the TTO
evaluation process was insignificantly affected by educa-
tion [33], whereas one Spanish study found that the level
of education did influence the values of health states
[34]. In our model, as the educational level was not
found to be a statistically significant variable, the impact
of the differences in educational level may not be crit-
ical. Finally, we did not collect morbidity information of
respondents as a limitation. In this reason, we cannot
exclude the opportunity of including COPD patients in
the survey, but we expected that such possibility might
be very low.
In conclusion, the utilities of various COPD health
states are likely dependent on the severity and exacerba-
tion of COPD. No differences were found between our
respondent groups, although systematic differences
existed between the VAS and TTO scores. Therefore,
intervention for the delay of disease progression and ap-
propriate prevention or management of exacerbation in
COPD will be helpful in order to improve the HRQOL
in COPD patients.Additional file
Additional file 1: Appendix 1. Descriptions of the COPD patients’
health status according to the severity. Appendix 2. Descriptions of
exacerbation according to the severity.
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